3 results
* To decrease mortality in MS-LCH by an early switch of patients with risk organ involvement, who do not respond to front-line therapy, to a more intensive treatment (Stratum III or Stratum IV).* To reduce reactivation rates and permanent…
This drug-drug interaction (DDI) study is being conducted to determine if there is a pharmacokinetic (PK) interaction between trametinib and the components of combination oral contraceptives (OCs), norethindrone (NE) and ethinyl estradiol (EE).…
primary objectives:* Part 1 (dose escalation): To determine therecommended Phase 2 dose(s) (RP2D[s]) forTAR-210* Part 2 (dose expansion): To determine thesafety of TAR-210 administered at theRP2D(s)for up to 12 monthsSecondary objectives (Parts 1…